Vancouver, Canada – December 11, 2024 – TheNewswire – Onco-Innovations Limited (CSE: ONCO) ("Onco" or the "Company") is pleased to be listed on the Canadian Securities Exchange (the “CSE”) and provides an overview of its achievements and future plans, as shared by the Company’s CEO, Mr. Thomas O’Shaughnessy.

 

“We are excited about our listing on the Canadian Securities Exchange (CSE) and encourage investors to review the recently filed prospectus and listing statement, which can be found on the Company’s profile on SEDAR+ at www.sedarplus.ca. This listing not only enhances our visibility in the market but also opens doors for greater access to funding, which we believe will enable us to accelerate our research and development initiatives. We believe this transition will position us favourably to attract potential investors and collaborators who share our vision of transforming cancer treatment.”

 

“Onco-Innovations is a preclinical stage biotechnology company focused on the commercialization of PNKP Inhibitor Technology, which has demonstrated the ability to enhance the effectiveness of current cancer treatments by specifically targeting cancer cells while sparing normal cells. Our technology targets a critical DNA repair enzyme, enabling more effective cancer therapy without harming healthy tissue. We have exclusive sublicenses for our PNKP Inhibitor Technology and hold several patents related to this innovative technology. Our team has made significant progress in the development of this therapy, and we are focused on further enhancing its potential to improve patient outcomes," Mr. O’Shaughnessy added.

 

"We are pleased to educate the market about our business, achievements and the groundbreaking work we are doing in cancer therapeutics. Our focus is now on accelerating the development of our PNKP Inhibitor Technology as we prepare for preclinical and clinical studies. Additionally, we are exploring the potential applications of our technology in other cancers. This is just the beginning of our journey, and we are eager to keep our investors informed as we progress, ensuring they fully understand our vision and the science that drives our innovations.”

 

The Company intends to issue future press releases informing investors about the key milestones it has achieved to date.

 

Mr. O’Shaughnessy, a seasoned health care executive and consulting leader, brings a wealth of experience in the healthcare and life sciences industry to Onco-Innovations. Following over a decade in the Ontario health sector, where he was part of the Province’s Health Results Team, Thomas joined KPMG’s national health practice and lead health advisory services in British Columbia. He has also been a Partner at Deloitte Canada, where he served high-profile health and life sciences clients, and held various senior roles in the partnership, including as National Leader for Clients and Growth for the firm’s health industry practice.

 

With over 24 years in health care and life sciences Mr. O’Shaughnessy has a proven track record in business and technology strategy development and execution, strategic management, digital health implementation, and senior stakeholder engagement. Educated at Oxford University, his leadership roles, also include Managing Principal at Carnarvon Strategies – Health Industry Solutions, underscoring his expertise in strategy execution, value creation, and growth within the health sector.

 

In addition, the Company is delighted to have Dr. Richard Heinzl as Director and Dr. Michael Weinfeld serving as Advisory Board members. Their expertise and leadership are expected to bring valuable contributions to the Company’s continued growth and success.

 

Dr. Heinzl is a physician, humanitarian, entrepreneur and author whose current focus is genomics, artificial intelligence and healthcare worldwide. He is currently CEO of My Next Health Inc., a next generation functional genomics AI company and is the founder of the Canadian chapter of Doctors without Borders. He was Global Medical Director for WorldCare Inc., a Boston-based, Harvard-associated virtual medicine company. He is a graduate of McMaster University’s Michael G. DeGroote School of Medicine and completed postgraduate degrees related to global health at Harvard University and the University of Oxford.

Dr. Weinfeld is a Professor in the Department of Oncology at the University of Alberta and a Senior Scientist with Alberta Health Services with over 40 years of cancer research experience. His laboratory is situated at the Cross Cancer Institute, Edmonton, Alberta. His primary area of research is DNA damage and repair with a special interest in translating discoveries into improving clinical outcomes of cancer therapy. His recent research has focused on the development of drugs intended to reduce the capacity of cancer cells to repair their DNA and thus render them more susceptible to radiotherapy and chemotherapeutic drugs that act by damaging DNA.

The Company is also pleased to announce that it has engaged the services of DS Market Solutions Inc. (email: davidsears@dsmarketsolutions.com, and website: dsmarketingsolution.com) (“DS Market”) to provide equity trading advisory and liquidity provider services in accordance with the policies of the Canadian Securities Exchange (“CSE”). DS Market will trade common shares of the Company on the CSE and all other trading venues with the objective of maintaining a reasonable market and improving the liquidity of the Company's common shares.

 

Under the terms of the engagement, DS Market will receive compensation of CAD$5,000 per month, payable monthly in advance. The engagement is on a month-to-month term and may be terminated by either party with thirty (30) days’ notice. There are no performance factors contained in the engagement and DS Market will not receive shares or options as compensation. DS Market and the Company are unrelated and unaffiliated entities and at the time of the engagement, neither DS Market nor its principals have an interest, directly or indirectly, in any securities of the Company. DS Market Solutions is an equity trading advisor to issuers looking to enhance liquidity in their publicly traded securities.

 

Additionally, the Company announces that it has engaged MCS Market Communication Service GmbH (business address: Rheinpromenade 13,40789 Monheim am Rhein, Nordrhein-Westfalen, Deutschland, email: info@mcsmarket.de; telephone: +491772481220; and website: www.mcsmarket.de)("MCS") for the provision of a range of online marketing services encompassing campaign creation, production of marketing materials, as well as research and analytics (the "Services").

 

The Services are expected to commence immediately and continue until June 2nd, 2025, or until budget exhaustion; provided, however, that the Services may be extended or shortened at the discretion of the Company depending on, among other things, the efficacy of the Services. The Company has agreed to pay to MCS EUR500,000 in consideration for the Services. The Company has not provided any securities to MCS or its principals as compensation for the Services. The Services will occur via digital channels Google Ads and native advertising.

About Onco-Innovations Limited

 

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented groundbreaking technology that targets solid tumours, setting new standards in cancer treatment. Onco’s commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.

 

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

  

Thomas O’Shaughnessy

Chief Executive Officer

 

For more information, please contact:

 

Thomas O’Shaughnessy

Chief Executive Officer

 

Tel: + 1 888 261 8055

investors@oncoinnovations.com

 

Forward Looking Information Disclaimer

 

This release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation based on current expectations, estimates, forecasts, projections, beliefs and assumptions made by management of the Company about the industry in which it operates. Forward-looking information may includes, but is not limited to, the prospect of advancing any of the Company’s current or future plans, financial and other projections, as well as statements regarding future plans, strategies, prospects, objectives or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts.

Forward-looking information is based on current expectations, assumptions, estimates, forecasts, projections, analysis and opinions of management made considering its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.

 

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

 

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.